Effects of Testosterone Supplementation on Body Composition in HIV Patients: A Meta-analysis of Double-blinded Randomized Controlled Trials

Abstract

This study was designed to evaluate the effects of testosterone supplementation (TS) on body composition in patients with HIV and the side effects of TS. A comprehensive literature search strategy was used to retrieve relevant randomized controlled trials (RCTs) examining the effects of TS on body composition. Atotal of 14 eligible studies were included, enrolling 388 and 349 randomized patients in TS and control groups, respectively. The quality of studies included was assessed, and data on total body weight (BW), lean body mass (LBM), fat mass (FM), serum total testosterone (TT), free testosterone (FT) levels, and adverse events were extracted and analyzed using Review Manager software 5.3. Meta-analysis results showed that TS was associated with a small but significant modification in total BW, serum TT, and FT levels in HIV-infected patients and in patients given various drug administrations. TS also significantly increased LBM in male patients, but no significant difference in LBM was observed between female counterparts treated with TS or not. Conversely, TS relative to placebo did not lead to a significant reduction in FM. No significant difference was observed between the two groups in terms of adverse effects. Our findings suggested that TS may be recommended to improve body composition in patients with HIV-related weight loss. However, owing to the high heterogeneity across included trials, further evaluations using large-scale, multi-center, blinded RCTs are needed.

Keywords

testosterone supplementation / body composition / HIV / meta-analysis

References

[1] BrandtC, ZvolenskyMJ, WoodsSP, et al.. Anxiety symptoms and disorders among adults living with HIV and AIDS: A critical review and integrative synthesis of the empirical literature. Clin Psychol Rev, 2017, 2(51): 164-184

[2] Lancet HIV, 2015, 2(10):

[3] ThibaultR, CanoN, PichardC. Quantification of lean tissue losses during cancer and HIV infection/AIDS. Curr Opin Clin Nutr Metab Care, 2011, 14(3): 261-267

[4] MaccioDR, CalfaG, RothGA. Oral testosterone in male rats and the development of experimental autoimmune encephalomyelitis. Neuroimmunomodulation, 2005, 12(4): 246-254

[5] PelucSI, ReedWL, McGrawKJ, et al.. Carotenoid supplementation and GnRH challenges influence female endocrine physiology, immune function, and egg-yolk characteristics in Japanese quail (Coturnix japonica). J Comp Physiol B, 2012, 182(5): 687-702

[6] ChenWC, ChenYM, HuangCC, et al.. Dehydroepiandrosterone supplementation combined with whole-body vibration training affects testosterone level and body composition in mice. Int J Med Sci, 2016, 13(10): 730-740

[7] Oaknin-BendahanS, AnisY, NirI, et al.. Effects of long-term administration of melatonin and a putative antagonist on the ageing rat. Neuroreport, 1995, 6(5): 785-788

[8] GomesAR, SouteiroP, SilvaCG, et al.. Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy. BMC Infect Dis, 2016, 16(1): 628

[9] KopickoJJ, MomoduI, AdedokunA, et al.. Characteristics of HIV-infected men with low serum testosterone levels. Int J STD AIDS, 1999, 10(12): 817-820

[10] GrinspoonS, CorcoranC, ParlmanK, et al.. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med, 2000, 133(5): 348-355

[11] HenggeUR, StocksK, WiehlerH, et al.. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS, 2003, 17(5): 699-710

[12] BhasinS, StorerTW, Asbel-SethiN, et al.. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab, 1998, 83(9): 3155-3162

[13] SardarP, JhaA, RoyD, et al.. Therapeutic effects of nandrolone and testosterone in adult male HIV patients with AIDS wasting syndrome (AWS): a randomized, double-blind, placebo-controlled trial. HIV Clin Trials, 2010, 11(4): 220-229

[14] Dolan LoobySE, CollinsM, LeeH, et al.. Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial. AIDS., 2009, 23(8): 951-959

[15] BhasinS, StorerTW, JavanbakhtM, et al.. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA, 2000, 283(6): 763-770

[16] StrawfordA, BarbieriT V, LoanM, et al.. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA, 1999, 281(14): 1282-1290

[17] GrunfeldC, KotlerDP, DobsA, et al.. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr, 2006, 41(3): 304-314

[18] BeigerJR, PallL, HallCD, et al.. Oxandrolone in AIDS-wasting myopathy. AIDS, 1996, 10(14): 1657-1662

[19] GrinspoonS, CorcoranC, AskariH, et al.. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 1998, 129(1): 18-26

[20] CoodleyGO, CoodleyMK. A trial of testosterone therapy for HIV-associated weight loss. AIDS, 1997, 11(11): 1347-1352

[21] DolanS, WilkieS, AliabadiN, et al.. Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: a randomized placebo-controlled study. Arch Intern Med, 2004, 164(8): 897-904

[22] DobsAS, CofrancescoJ, NoltenWE, et al.. The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med, 1999, 107(2): 126-132

[23] MillerK, CorcoranC, ArmstrongC, et al.. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab, 1998, 83(8): 2717-2725

[24] ChoiHH, GrayPB, StorerTW, et al.. Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. J Clin Endocrinol Metab, 2005, 90(3): 1531-1541

[25] GonzalezAM, HoffmanJR, JajtnerAR, et al.. Protein supplementation does not alter intramuscular anabolic signaling or endocrine response after resistance exercise in trained men. Nutr Res, 2015, 35(11): 990-1000

[26] MupereE, MaloneL, ZalwangoS, et al.. Lean tissue mass wasting is associated with increased risk of mortality among women with pulmonary tuberculosis in urban Uganda. Ann Epidemiol, 2012, 22(7): 466-473

[27] KongA, EdmondsP. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis, 2002, 2(11): 692-699

[28] BhasinS, CalofOM, StorerTW, et al.. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab, 2006, 2(3): 146-159

[29] CoronaG, GiagulliVA, MaseroliE, et al.. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest, 2016, 39(9): 967-981

[30] MulliganK, ZackinR V, RoennJH, et al.. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab, 2007, 92(2): 563-570

[31] Bailey-DownsLC, SosnowskaD, TothP, et al.. Growth hormone and IGF-1 deficiency exacerbate high-fat diet-induced endothelial impairment in obese Lewis dwarf rats: implications for vascular aging. J Gerontol A Biol Sci Med Sci, 2012, 67(6): 553-564

[32] Sinha-HikimI, ArtazaJ, WoodhouseL, et al.. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab, 2002, 283(1): E154-E164

[33] DuboisV, LaurentMR, SinnesaelM, et al.. A satellite cell-specific knockout of the androgen receptor reveals myostatin as a direct androgen target in skeletal muscle. FASEB J, 2014, 28(7): 2979-2994

[34] GiannoulisMG, MartinFC, NairKS, et al.. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev, 2012, 33(3): 314-377

[35] LiuX, ChengYI, PanQI, et al.. Changes in mitotic reorientation and Wnt/AR signaling in rat prostate epithelial cells exposed to subchronic testosterone. Exp TherMed, 2016, 11(4): 1361-1366